Collegium Pharmaceutical (COLL) shares rallied 10.6% in the last trading session to close at $38.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7% gain over the past four weeks. This specialty pharmaceutical company is expected to post quarterly earnings of $1.45 per share in its upcoming report, which represents a year-over-year change of +15.1%. Revenues are expected to be $142.2 million, up 4.9% from ...

– Acquisition Funded by Collegium's Cash on Hand and New Five-Year Financing with Significantly Improved Terms – STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive agreement pursuant to which Collegium will acquire Ironshore for $525 million in cash with the potential for an additional $25 million commercial milestone payment. Transaction Rationale Under the terms of th ...

– Adds Commercial Product Jornay PM®, Establishing Collegium's Presence in Neurology (ADHD) – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Collegium Estimates Q2'24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms 2024 Financial Guidance for the Current Business – STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive ...

FDA Approval and Exclusivity - FDA granted pediatric exclusivity for Nucynta and Nucynta ER, extending U.S. exclusivity for Nucynta to January 3, 2027, and for Nucynta ER to December 27, 2025 [3] - The pediatric exclusivity enhances the value of the Nucynta franchise and strengthens the company's near-term outlook [1] Product Indications and Usage - Nucynta ER is approved for managing severe and persistent pain in adults requiring extended opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy [1] - Nucynta tablets are indicated for acute pain in adults and pediatric patients aged six years and older with a body weight of at least 40 kg [18][22] Market and Commercialization - The company focuses on improving the lives of people with serious medical conditions through its diversified specialty pharmaceutical products [4] - The extension of exclusivity for Nucynta and Nucynta ER provides a competitive advantage in the U.S. market [3] Regulatory and Safety Information - Nucynta ER and Nucynta tablets carry significant risks, including addiction, abuse, misuse, and life-threatening respiratory depression [17][32] - Healthcare providers are encouraged to complete REMS-compliant education programs to ensure safe use of Nucynta products [17] Forward-Looking Statements - The company's forward-looking statements include expectations regarding market opportunities, financial performance, and product commercialization [11][12] - Risks such as regulatory challenges, market competition, and intellectual property protection could impact future performance [11]

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Mike Heffernan - Chairman Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Oren Livnat - H.C. Wainwright Operator Greetings. And welcome to the Collegium Pharmaceutical F ...

For the quarter ended March 2024, Collegium Pharmaceutical (COLL) reported revenue of $144.92 million, up 0.1% over the same period last year. EPS came in at $1.45, compared to $1.32 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $147.04 million, representing a surprise of -1.44%. The company delivered an EPS surprise of -2.68%, with the consensus EPS estimate being $1.49.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.45 per share, missing the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.68%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.33 per share when it actually produced earnings of $1.58, delivering a surprise of 18.80%.Over th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State o ...

Exhibit 99.1 Collegium Reports First Quarter 2024 Financial Results – Generated Q1'24 Net Revenue of $144.9 Million – – Delivered Q1'24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1'24 GAAP Net Income of $27.7 Million vs. Q1'23 GAAP Net Loss of $(17.4) Million – – Delivered Q1'24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Reaf irmed Full-Year 2024 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 9, ...

– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that effective May 24, 2024, ...